VIR Q3 2025 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$240,000-89.9% YoY

Gross Profit

-$151M-63005.0% margin

Operating Income

-$173M-72267.9% margin

Net Income

-$163M-67975.4% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

-80.2%

Cash Flow

Operating Cash Flow

-$168M

Free Cash Flow

-$168M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$223M

Stockholders' Equity

$796M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$240,000	$2M	-89.9%
Gross Profit	-$151M	-$193M	+21.6%
Operating Income	-$173M	-$231M	+25.0%
Net Income	-$163M	-$214M	+23.7%

Revenue Segments

Grant

$305,000100%

Geographic Segments

UNITED STATES

$305,000100%